Qiagen (QGEN) was Upgraded to a Buy Rating at Kepler Capital

In a report issued on July 9, Maja Pataki from Kepler Capital upgraded Qiagen (QGENResearch Report) to Buy, with a price target of EUR51.00. The company’s shares closed last Friday at $50.52.

According to TipRanks.com, Pataki is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -12.8% and a 33.7% success rate. Pataki covers the Healthcare sector, focusing on stocks such as Siemens Healthineers AG, Koninklijke Philips, and Tecan Group AG.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Qiagen with a $58.88 average price target.

See today’s analyst top recommended stocks >>

Qiagen’s market cap is currently $11.54B and has a P/E ratio of 25.80. The company has a Price to Book ratio of -62.15.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.